13D Filings
Home
FAQ
JADE BIOSCIENCES, INC.
JBIO
Amendment
Ownership

0.20%

Total Shares

51,406

Issuer CIK

1798749

CUSIP

008064206

Event Date

Apr 27, 2025

Accepted

Apr 30, 2025, 04:29 PM

SEC EDGARView Original Filing
Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Atlas Venture Fund XII, L.P.
Partnership
0.20%50,992050,992
Atlas Venture Associates XII, L.P.
Partnership
0.20%51,406051,406
Atlas Venture Associates XII, LLC
Other
0.20%51,406051,406
Disclosure Items (3)

Security Title

Common Stock

Issuer Name

JADE BIOSCIENCES, INC.

Issuer Address

930 WINTER STREET, WALTHAM, MA, 02451

On October 30, 2024, Aerovate, entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Aerovate, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Aerovate ("Merger Sub I"), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Aerovate ("Merger Sub II" and together with Merger Sub I, "Merger Subs"), and Jade Biosciences, Inc., a Delaware corporation ("Jade"), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I would merge with and into Jade, with Jade surviving the merger as the surviving corporation (the "First Merger"), and as part of the same overall transaction, Jade would merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the "Second Merger" and together with the First Merger, the "Merger"). On April 16, 2025, Aerovate held a special meeting in lieu of the annual meeting of Aerovate stockholders at which Aerovate's stockholders approved the Merger, along with a reverse stock split of Aerovate's common stock to be effected at the discretion of the Aerovate Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 28, 2025, the reverse stock split was effected at a ratio of 1-for-35. Immediately thereafter, on April 28, 2025, the Merger closed. The Reporting Persons are filing this Amendment to Statement on Schedule 13D to report the dilution of their beneficial ownership by virtue of the completion of the Merger.

Percentage of Class

As of the date hereof, Atlas XII is the record owner of 50,992 shares of Common Stock. AVA XII LP is the general partner of Atlas XII and AVA XII LLC is the general partner of AVA XII LP. Each of Atlas XII, AVA XII LP and AVA XII LLC has shared voting and dispositive power over the shares held by Atlas XII. As such, each of Atlas XII, AVA XII LP and AVA XII LLC may be deemed to beneficially own the shares held by Atlas XII. As of the date hereof, AVA XII LP is the record owner of 414 shares of Common Stock. AVA XII LLC is the general partner of AVA XII LP. Each of AVA XII LP and AVA XII LLC has shared voting and dispositive power over the shares held by AVA XII LP. As such, each of AVA XII LP and AVA XII LLC may be deemed to beneficially own the shares held by AVA XII LP. Collectively, the Reporting Persons may be deemed to beneficially own 0.2% of the Issuer's outstanding Common Stock, which percentage is calculated based upon 32,235,927 outstanding shares of Common Stock of the Issuer, as reported to the Reporting Persons by the Issuer. The Reporting Persons disclaim group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.

Number of Shares

As of the date hereof, Atlas XII has shared voting power and shared dispositive power over 50,992 shares of Common Stock. As of the date hereof, AVA XII LP sole has shared voting power and shared dispositive power over 51,406 shares of Common Stock. As of the date hereof, AVA XII LLC sole has shared voting power and shared dispositive power over 51,406 shares of Common Stock.

Transactions

Except as described herein, none of the Reporting Persons have purchased or sold any shares of Common Stock during the past 60 days.

Shareholders

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

Date of 5% Ownership

The Reporting Persons ceased to be beneficial owner of more than five percent on April 28, 2025 following the closing of the Merger.